Subscribe
shutterstock_1548709493_nitpicker
nitpicker / Shutterstock.com
13 May 2022GenericsAlex Baldwin

BMS says Hengrui’s Abraxane infringes

A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane (paclitaxel) infringes a patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
BMS sues AstraZeneca for infringing cancer treatment drug
26 January 2023   US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
BMS sues AstraZeneca for infringing cancer treatment drug
26 January 2023   US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

More on this story

Big Pharma
BMS sues AstraZeneca for infringing cancer treatment drug
26 January 2023   US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB